Search Results

Tenax Therapeutics, Inc. today announced that it will participate in the 36th Annual Roth Conference in Dana Point, California, from March 17-19, 2024.

Tenax Therapeutics, Inc. (Nasdaq: TENX), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, announced financial results for the first quarter of 2024 and provided a corporate update.

Tenax Therapeutics, Inc. (Nasdaq: TENX) announced full year 2023 financial results, and provided clinical development and business updates.

Tenax Therapeutics, Inc. today announced that Stuart Rich, Tenax CMO, will moderate ”LEVEL Setting,” a scientific round-table exploration of the rationale for TNX-103 (oral levosimendan), for the treatment of PH-HFpEF.

Tenax Therapeutics, Inc. today announced Dr. Sanjiv Shah will present data and review the scientific basis for the use of levosimendan in PH-HFpEF.

Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today shared the results of a study published in the journal Pulmonary Therapy, demonstrating the association of portable oxygen concentrators with increased survival and cost-effectiveness ratio when compared to other long-term oxygen therapies.

Tenax Therapeutics, Inc. today announced it has secured global development, commercial, and IP rights to oral and subcutaneous levosimendan for the treatment of pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF).

Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, announced today that the United States Patent and Trademark Office (USPTO) has allowed its patent application with claims covering the use of TNX-103 (oral levosimendan).

Tenax Therapeutics, Inc. announced the pricing of a public offering of 1,600,000 shares of its common stock and warrants to purchase up to 3,200,000 shares of its common stock at a purchase price of $5.65 per share and associated Common Warrant.

Tenax Therapeutics, Inc. announced that the United States Patent and Trademark Office has granted the Company a patent covering the use of TNX-103, TNX-102, TNX-101, the active metabolites of levosimendan and various combinations of cardiovascular drugs with levosimendan when used to improve exercise performance in PH-HFpEF patients.